Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

430
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

162
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

The efficacy of camel milk and Tarangabin (manna of Alhagi maurorum( combination therapy on glomerular filtration rate in patients with chronic kidney disease: A randomized controlled trial

Pages

  170-180

Keywords

Tarangabin (manna of Alhagi maurorum) 
Chronic kidney disease (CKD) 
Glomerular filtration rate (GFR) 

Abstract

 Objective: This study was designed to investigate the effect of Camel milk and Tarangabin (manna of Alhagi maurorum) combination therapy in addition to conventional treatments in patients with chronic kidney disease (CKD). Materials and Methods: Forty-four patients of 15 to 70 years old, with CKD due to hypertension or diabetes, and estimated glomerular filtration rate (eGFR) of 15– 60 ml/min per 1. 73 m2, were enrolled in this trial. The patients were randomized to receive either 400 cc of Camel milk with 10 cc of Tarangabin syrup orally in two divided daily doses for 3 months plus conventional therapy or conventional therapy alone. The conventional treatment included diabetes medications and angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Results: The baseline characteristics of patients were similar in the two groups. Serum levels of creatinine (p=0. 01), blood levels of urea nitrogen (p=0. 0001), triglyceride (p=0. 02), and potassium (p=0. 05), and diastolic blood pressure (p=0. 0001) decreased, while eGFR (p=0. 001) improved in intervention group significantly. Conclusion: It seems that the therapeutic protocol used in this study can improve renal function in patients with CKD through regulating glucose and anti-inflammatory, laxative, and immunostimulatory properties.

Cites

  • No record.

    • References

    Cite

    APA: Copy

    HOSEINI, SEYED MOUSALREZA, ANUSHIRAVANI, MAJID, MOJAHEDI, MOHAMMAD JAVAD, HAMI, MARYAM, ZIBAEE, SAEID, RAKHSHANDEH, HASSAN, TAGHIPOUR, ALI, NIKAKHTAR, ZAHRA, ESHRAGHI, HAMID, & Tavassoli, Amir Parviz. (2020). The efficacy of camel milk and Tarangabin (manna of Alhagi maurorum( combination therapy on glomerular filtration rate in patients with chronic kidney disease: A randomized controlled trial. AVICENNA JOURNAL OF PHYTOMEDICINE (AJP), 10(2), 170-180. SID. https://sid.ir/paper/326489/en

    Vancouver: Copy

    HOSEINI SEYED MOUSALREZA, ANUSHIRAVANI MAJID, MOJAHEDI MOHAMMAD JAVAD, HAMI MARYAM, ZIBAEE SAEID, RAKHSHANDEH HASSAN, TAGHIPOUR ALI, NIKAKHTAR ZAHRA, ESHRAGHI HAMID, Tavassoli Amir Parviz. The efficacy of camel milk and Tarangabin (manna of Alhagi maurorum( combination therapy on glomerular filtration rate in patients with chronic kidney disease: A randomized controlled trial. AVICENNA JOURNAL OF PHYTOMEDICINE (AJP)[Internet]. 2020;10(2):170-180. Available from: https://sid.ir/paper/326489/en

    IEEE: Copy

    SEYED MOUSALREZA HOSEINI, MAJID ANUSHIRAVANI, MOHAMMAD JAVAD MOJAHEDI, MARYAM HAMI, SAEID ZIBAEE, HASSAN RAKHSHANDEH, ALI TAGHIPOUR, ZAHRA NIKAKHTAR, HAMID ESHRAGHI, and Amir Parviz Tavassoli, “The efficacy of camel milk and Tarangabin (manna of Alhagi maurorum( combination therapy on glomerular filtration rate in patients with chronic kidney disease: A randomized controlled trial,” AVICENNA JOURNAL OF PHYTOMEDICINE (AJP), vol. 10, no. 2, pp. 170–180, 2020, [Online]. Available: https://sid.ir/paper/326489/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top